JPH08511537A - 神経筋疾患および症状を処置するためのボツリヌス毒素組み合わせ - Google Patents
神経筋疾患および症状を処置するためのボツリヌス毒素組み合わせInfo
- Publication number
- JPH08511537A JPH08511537A JP7502051A JP50205195A JPH08511537A JP H08511537 A JPH08511537 A JP H08511537A JP 7502051 A JP7502051 A JP 7502051A JP 50205195 A JP50205195 A JP 50205195A JP H08511537 A JPH08511537 A JP H08511537A
- Authority
- JP
- Japan
- Prior art keywords
- botulinum toxin
- toxin type
- neurotoxin
- botulinum
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.神経筋疾患または症状の患者を処置する方法であって、A、B、C、D、 E、FおよびG型のボツリヌス毒素から成る群から選択する少なくとも2種の神 経毒の組み合わせを、処置有効量で患者に投与することを含んで成り、選択した 各神経毒の量は、投与する組み合わせの処置活性の持続時間を調節するよう選択 する方法。 2.選択した神経毒は、A型およびB型のボツリヌス毒素である請求項1記載 の方法。 3.選択した神経毒は、A型およびC型のボツリヌス毒素である請求項1記載 の方法。 4.選択した神経毒は、A型およびD型のボツリヌス毒素である請求項1記載 の方法。 5.選択した神経毒は、A型およびE型のボツリヌス毒素である請求項1記載 の方法。 6.選択した神経毒は、A型およびF型のボツリヌス毒素である請求項1記載 の方法。 7.選択した神経毒は、A型およびG型のボツリヌス毒素である請求項1記載 の方法。 8.処置活性の持続時間は、関節脱臼の処置、物理療法のための弛緩、筋肉痙 縮の軽減、手術を受ける関節の不動化、および術前または術後の筋肉収縮の防止 に適当である請求項1記載の方法。 9.処置活性の持続時間は、腱および靭帯線維の修復、側彎および括約筋痙縮 の処置に適当である請求項1記載の方法。 10.神経筋疾患または症状の患者を処置する方法であって、ボツリヌス毒素 の処置活性を短期間延長するために、A型ボツリヌス毒素を処置有効量で患者に 投与し、ある時間の経過後、B、C、D、E、FおよびG型のボツリヌス毒素か ら成る群から選択する少なくとも1種の神経毒を、処置有効量で患者に投与する ことを含んで成る方法。 11.選択した神経毒はB型ボツリヌス毒素から成る請求項10記載の方法。 12.選択した神経毒はC型ボツリヌス毒素から成る請求項10記載の方法。 13.選択した神経毒はD型ボツリヌス毒素から成る請求項10記載の方法。 14.選択した神経毒はE型ボツリヌス毒素から成る請求項10記載の方法。 15.選択した神経毒はF型ボツリヌス毒素から成る請求項10記載の方法。 16.選択した神経毒はG型ボツリヌス毒素から成る請求項10記載の方法。 17.神経筋疾患または症状の患者を処置するのに適当な組成物であって、A 、B、C、D、E、FおよびG型のボツリヌス毒素から成る群から選択する少な くとも2種の神経毒の組み合わせを処置有効量で含有し、選択した各神経毒の量 は、投与する組み合わせの処置活性の持続時間を調節するよう選択した組成物。 18.選択した神経毒は、A型およびB型のボツリヌス毒素である請求項17 記載の組成物。 19.選択した神経毒は、A型およびC型のボツリヌス毒素である請求項17 記載の組成物。 20.選択した神経毒は、A型およびD型のボツリヌス毒素である請求項17 記載の組成物。 21.選択した神経毒は、A型およびE型のボツリヌス毒素である請求項17 記載の組成物。 22.選択した神経毒は、A型およびF型のボツリヌス毒素である請求項17 記載の組成物。 23.選択した神経毒は、A型およびG型のボツリヌス毒素である請求項17 記載の組成物。 24.処置活性の持続時間は、関節脱臼の処置、物理療法のための弛緩、筋肉 痙縮の軽減、手術を受ける関節の不動化、および術前または術前または術後の筋 肉収縮の防止に適当である請求項17記載の組成物。 25.処置活性の持続時間は、腱および靭帯腺維の修復、側彎および括約筋痙 攣の処置に適当である請求項17記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7503293A | 1993-06-10 | 1993-06-10 | |
US08/075,032 | 1993-06-10 | ||
PCT/US1994/006418 WO1994028923A1 (en) | 1993-06-10 | 1994-06-07 | Multiple botulinum toxins for treating neuromuscular disorders and conditions |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005274365A Division JP2006052227A (ja) | 1993-06-10 | 2005-09-21 | 神経筋疾患および症状を処置するためのボツリヌス毒素組み合わせ |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08511537A true JPH08511537A (ja) | 1996-12-03 |
JP4249802B2 JP4249802B2 (ja) | 2009-04-08 |
Family
ID=22123106
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50205195A Expired - Fee Related JP4249802B2 (ja) | 1993-06-10 | 1994-06-07 | 神経筋疾患および症状を処置するためのボツリヌス毒素組み合わせ |
JP2005274365A Pending JP2006052227A (ja) | 1993-06-10 | 2005-09-21 | 神経筋疾患および症状を処置するためのボツリヌス毒素組み合わせ |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005274365A Pending JP2006052227A (ja) | 1993-06-10 | 2005-09-21 | 神経筋疾患および症状を処置するためのボツリヌス毒素組み合わせ |
Country Status (8)
Country | Link |
---|---|
US (1) | US20010021695A1 (ja) |
EP (1) | EP0702559B1 (ja) |
JP (2) | JP4249802B2 (ja) |
AU (1) | AU683275B2 (ja) |
CA (1) | CA2164626C (ja) |
DE (1) | DE69432299T2 (ja) |
ES (1) | ES2194025T3 (ja) |
WO (1) | WO1994028923A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7429387B2 (en) | 1997-07-15 | 2008-09-30 | The Regents Of The University Of Colorado | Use of botulinum toxin therapy for treatment of recalcitrant voiding dysfunction |
US7449192B2 (en) | 1997-07-15 | 2008-11-11 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction |
US7455845B2 (en) | 1997-07-15 | 2008-11-25 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure |
US7470431B2 (en) | 1997-07-15 | 2008-12-30 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer |
US7968104B2 (en) | 1997-07-15 | 2011-06-28 | Allergan, Inc. | Use of neurotoxin therapy for treatment of urologic and related disorders |
JP2012229263A (ja) * | 2000-10-04 | 2012-11-22 | Allergan Inc | 筋肉損傷の処置方法 |
US9139624B2 (en) | 1998-01-26 | 2015-09-22 | Bal Ram Singh | Biologically active hemagglutinin from type a Clostridium botulinum and methods of use |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9120306D0 (en) | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
WO1994000481A1 (en) * | 1992-06-23 | 1994-01-06 | Associated Synapse Biologics | Pharmaceutical composition containing botulinum b complex |
US6974578B1 (en) | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
AU2007202480B2 (en) * | 1993-12-28 | 2009-01-29 | Allergan, Inc. | Method for treating pain associated with a muscle disorder |
US8557256B2 (en) | 1993-12-28 | 2013-10-15 | Allergan, Inc. | Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin |
US8187612B2 (en) | 1993-12-28 | 2012-05-29 | Allergan, Inc. | Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle |
EP0737074B1 (en) * | 1993-12-28 | 2001-08-01 | Allergan Sales, Inc. | Botulinum toxins for treating hyperhydrosis |
US5766605A (en) * | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
GB9508204D0 (en) * | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
DK0773788T3 (da) * | 1995-06-06 | 2003-09-01 | Allergan Inc | Forbedrede præparater og fremgangsmåder til kemodenervering under anvendelse af neurotoxiner |
EP0845267B1 (en) * | 1996-11-27 | 2002-04-24 | William J. Binder | Neurotoxins for treating cutaneous disorders in mammals |
GB9721189D0 (en) * | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
TW574036B (en) | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
AU1706400A (en) * | 1998-10-27 | 2000-05-15 | Mayo Foundation For Medical Education And Research | Methods for enhancing wound healing |
DE19856897A1 (de) | 1998-12-10 | 2000-06-15 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum zur Unterdrückung von Schnarchgeräuschen |
GB9907429D0 (en) | 1999-03-31 | 1999-05-26 | Microbiological Res Authority | Modulation of C-fibre activity |
DE19925739A1 (de) | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
DE10035156A1 (de) * | 2000-07-19 | 2002-02-07 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel |
EP1611901B1 (en) | 2003-03-13 | 2013-07-10 | Eisai R&D Management Co., Ltd. | Preventive or remedy for teeth grinding |
ES2373963T3 (es) * | 2004-09-23 | 2012-02-10 | Toxcure, Inc. | Tratamiento de neoplasmas con neurotoxina. |
US8343929B2 (en) * | 2004-09-23 | 2013-01-01 | Toxcure, Inc. | Treating neoplasms with neurotoxin |
AU2006340711C1 (en) | 2005-04-05 | 2013-02-07 | Allergan, Inc. | Clostridial toxin activity assays |
US8105611B2 (en) * | 2005-06-17 | 2012-01-31 | Allergan, Inc. | Treatment of autoimmune disorder with a neurotoxin |
FR2896693B1 (fr) * | 2006-01-27 | 2008-03-14 | Sod Conseils Rech Applic | Composition comprenant plusieurs toxines botuliques |
WO2009139739A1 (en) * | 2006-02-14 | 2009-11-19 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions comprising a combination of botulinum toxin a and botulinum toxin b for treating conditions characterized by unwanted or excessive presynaptic neuronal activity or secretion |
US20130171122A1 (en) * | 2011-12-29 | 2013-07-04 | Allergan, Inc. | Endopeptidase and neurotoxin combination treatment of bladder disorders |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9120306D0 (en) * | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
WO1994000481A1 (en) * | 1992-06-23 | 1994-01-06 | Associated Synapse Biologics | Pharmaceutical composition containing botulinum b complex |
-
1994
- 1994-06-07 CA CA002164626A patent/CA2164626C/en not_active Expired - Lifetime
- 1994-06-07 AU AU71018/94A patent/AU683275B2/en not_active Expired
- 1994-06-07 EP EP94920108A patent/EP0702559B1/en not_active Expired - Lifetime
- 1994-06-07 DE DE69432299T patent/DE69432299T2/de not_active Expired - Lifetime
- 1994-06-07 ES ES94920108T patent/ES2194025T3/es not_active Expired - Lifetime
- 1994-06-07 WO PCT/US1994/006418 patent/WO1994028923A1/en active IP Right Grant
- 1994-06-07 JP JP50205195A patent/JP4249802B2/ja not_active Expired - Fee Related
-
2001
- 2001-04-30 US US09/845,514 patent/US20010021695A1/en not_active Abandoned
-
2005
- 2005-09-21 JP JP2005274365A patent/JP2006052227A/ja active Pending
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7429387B2 (en) | 1997-07-15 | 2008-09-30 | The Regents Of The University Of Colorado | Use of botulinum toxin therapy for treatment of recalcitrant voiding dysfunction |
US7449192B2 (en) | 1997-07-15 | 2008-11-11 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction |
US7455845B2 (en) | 1997-07-15 | 2008-11-25 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure |
US7470431B2 (en) | 1997-07-15 | 2008-12-30 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer |
US7968104B2 (en) | 1997-07-15 | 2011-06-28 | Allergan, Inc. | Use of neurotoxin therapy for treatment of urologic and related disorders |
US8057807B2 (en) | 1997-07-15 | 2011-11-15 | The Regents Of The University Of Colorado, A Body Corporate | Use of botulinum toxin therapy for treatment of recalcitrant voiding dysfunction |
US8062643B2 (en) | 1997-07-15 | 2011-11-22 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urologic and related disorders |
US8840905B2 (en) | 1997-07-15 | 2014-09-23 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urologic and related disorders |
US9066943B2 (en) | 1997-07-15 | 2015-06-30 | The Regents Of The University Of Colorado | Use of botulinum toxin therapy for treatment of urological neurological conditions |
US9139624B2 (en) | 1998-01-26 | 2015-09-22 | Bal Ram Singh | Biologically active hemagglutinin from type a Clostridium botulinum and methods of use |
JP2012229263A (ja) * | 2000-10-04 | 2012-11-22 | Allergan Inc | 筋肉損傷の処置方法 |
Also Published As
Publication number | Publication date |
---|---|
CA2164626A1 (en) | 1994-12-22 |
AU683275B2 (en) | 1997-11-06 |
CA2164626C (en) | 2004-11-23 |
ES2194025T3 (es) | 2003-11-16 |
US20010021695A1 (en) | 2001-09-13 |
EP0702559B1 (en) | 2003-03-19 |
JP2006052227A (ja) | 2006-02-23 |
AU7101894A (en) | 1995-01-03 |
DE69432299D1 (de) | 2003-04-24 |
WO1994028923A1 (en) | 1994-12-22 |
EP0702559A1 (en) | 1996-03-27 |
JP4249802B2 (ja) | 2009-04-08 |
DE69432299T2 (de) | 2003-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH08511537A (ja) | 神経筋疾患および症状を処置するためのボツリヌス毒素組み合わせ | |
JPH08511536A (ja) | 複数の血清型のボツリヌス毒素により、神経筋疾患および症状を処置する方法 | |
JP3238154B2 (ja) | 過度の発汗を軽減するためのボツリヌス毒素含有医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040907 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20041206 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050131 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050302 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050524 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20051117 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090116 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120123 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130123 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |